Medeon Biodesign (ROCO:6499) Short-Term Debt: NT$0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6499 Medeon Biodesign Inc ROCO:6499
63 GF Score
Price NT$63.30
GF Value NT$107.13
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Medeon Biodesign Short-Term Debt?

Medeon Biodesign ROCO:6499 +2.10% 63 Short-Term Debt is NT$0.0 Mil as of Mar. 2026. GuruFocus rates ROCO:6499 with a GF Score™ of 63/100 and a GF Value™ of NT$107.13 (Possible Value Trap). The stock has 2 warning signs investors should review.

Medeon Biodesign's Short-Term Debt for the quarter that ended in Mar. 2026 was NT$0.0 Mil.

Medeon Biodesign Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Medeon Biodesign Short-Term Debt Related Terms

Medeon Biodesign Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Medeon Biodesign's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medeon Biodesign Short-Term Debt Chart

Medeon Biodesign Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medeon Biodesign Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6499
63GF Score
Medeon Biodesign Inc ROCO:6499
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of NT$0.0 Mil mean?
Medeon Biodesign (ROCO:6499) has a Short-Term Debt of NT$0.0 Mil as of Mar. 2026.
Is Medeon Biodesign's Short-Term Debt too high?
Medeon Biodesign's current Short-Term Debt is NT$0.0 Mil. Overall, Medeon Biodesign has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's Short-Term Debt compare to ISRG and BDX?
Medeon Biodesign's Short-Term Debt of NT$0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Medeon Biodesign's current Short-Term Debt is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Possible Value Trap. The stock's GF Value™ is NT$107.13, compared to a current price of NT$63.30 — trading 40.9% below its estimated fair value. The current Short-Term Debt is NT$0.0 Mil. Medeon Biodesign's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current Short-Term Debt is NT$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?

Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued. The current stock price of NT$63.30 is trading 40.9% below its estimated GF Value™ of NT$107.13. GuruFocus considers Medeon Biodesign to be Possible Value Trap.

Key valuation signals for ROCO:6499:

  • Short-Term Debt: NT$0.0 Mil
  • GF Value™: NT$107.13 vs. price of NT$63.30 (40.9% below fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medeon Biodesign Business Description

Address No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
63GF Score

Get the complete analysis for ROCO:6499

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$63.30
Price
NT$107.13
GF Value